Paper42699720
Immunohistochemical Expression of Programmed Death-Ligand 1 (PD-L1) in Breast Carcinoma and Its Correlation With Estrogen Receptor, Progesterone Receptor and HER2/neu Status: A Single-Centre Study From Central India.
Dubey P and 2 others. Cureus, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Immunohistochemical Expression of Programmed Death-Ligand 1 (PD-L1) in Breast Carcinoma and Its Correlation With Estrogen Receptor, Progesterone Receptor and HER2/neu Status: A Single-Centre Study From Central India. Papers, record 42699720. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42699720
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Immunohistochemical Expression of Programmed Death-Ligand 1 (PD-L1) in Breast Carcinoma and Its Correlation With Estrogen Receptor, Progesterone Receptor and HER2/neu Status: A Single-Centre Study From Central India.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31548545 | Breast cancer. | Nat Rev Dis Primers | 2019 | https://conductscience.org/library/papers/31548545 | PubMed |
| 2 | 32673076 | Cancer Statistics, 2020: Report From National Cancer Registry Programme, India. | JCO Glob Oncol | 2020 | https://conductscience.org/library/papers/32673076 | PubMed |
| 3 | 26364145 | Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. | Clin Breast Cancer | 2016 | https://conductscience.org/library/papers/26364145 | PubMed |
| 4 | 32164163 | Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32164163 | PubMed |
| 5 | 24842267 | Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. | Breast Cancer Res Treat | 2014 | https://conductscience.org/library/papers/24842267 | PubMed |
| 6 | 24647569 | In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/24647569 | PubMed |
| 7 | 30524905 | Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival. | Oncoimmunology | 2018 | https://conductscience.org/library/papers/30524905 | PubMed |
| 8 | 11135226 | COX-2 is expressed in human pulmonary, colonic, and mammary tumors. | Cancer | 2000 | https://conductscience.org/library/papers/11135226 | PubMed |
| 9 | 30201790 | Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. | BMJ | 2018 | https://conductscience.org/library/papers/30201790 | PubMed |
| 10 | 28801156 | Alarming Burden of Triple-Negative Breast Cancer in India. | Clin Breast Cancer | 2018 | https://conductscience.org/library/papers/28801156 | PubMed |
| 11 | 34097070 | PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. | J Natl Cancer Inst | 2021 | https://conductscience.org/library/papers/34097070 | PubMed |
| 12 | 25669979 | Prognostic and predictive value of PDL1 expression in breast cancer. | Oncotarget | 2015 | https://conductscience.org/library/papers/25669979 | PubMed |
| 13 | 29846104 | Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. | Arch Pathol Lab Med | 2018 | https://conductscience.org/library/papers/29846104 | PubMed |
| 14 | 28079291 | Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis. | Breast J | 2017 | https://conductscience.org/library/papers/28079291 | PubMed |
| 15 | 35139274 | Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35139274 | PubMed |
| 16 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 17 | 27184417 | Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. | Nat Rev Clin Oncol | 2016 | https://conductscience.org/library/papers/27184417 | PubMed |
| 18 | 10963602 | Molecular portraits of human breast tumours. | Nature | 2000 | https://conductscience.org/library/papers/10963602 | PubMed |
| 19 | 20586616 | American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). | Arch Pathol Lab Med | 2010 | https://conductscience.org/library/papers/20586616 | PubMed |
| 20 | 16611412 | The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. | Neoplasia | 2006 | https://conductscience.org/library/papers/16611412 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| NR4A1 | 3164 | PubTator's text mining | https://conductscience.org/library/genes/3164 | NCBI Gene |
| PGR | 5241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42699720
GET https://conductscience.org/api/papers/v1/42699720/references?page=2